Sir Roger Penrose, a name synonymous with genius, has tirelessly pursued the secrets of the universe with the fervour of a true renaissance seer. His intellectual contributions span a breathtaking range, from the intricate beauty of Penrose tilings to the vast expanse of cosmology, and even the enigmatic depths of human consciousness.
Surprisingly, the organoids were still healthy when they returned from orbit a month later, but the cells had matured faster compared to identical organoids grown on Earth—they were closer to becoming adult neurons and were beginning to show signs of specialization. The results, which could shed light on potential neurological effects of space travel, were published on October 23, 2024, in Stem Cells Translational Medicine.
“The fact that these cells survived in space was a big surprise,” says co-senior author Jeanne Loring, PhD, professor emeritus in the Department of Molecular Medicine and founding director of the Center for Regenerative Medicine at Scripps Research. “This lays the groundwork for future experiments in space, in which we can include other parts of the brain that are affected by neurodegenerative disease.”
On Earth, the team used stem cells to create organoids consisting of either cortical or dopaminergic neurons, which are the neuronal populations impacted in multiple sclerosis and Parkinson’s disease—diseases that Loring has studied for decades. Some organoids also included microglia, a type of immune cell that is resident within the brain, to examine the impact of microgravity on inflammation.
Abstract. Research conducted on the International Space Station (ISS) in low-Earth orbit (LEO) has shown the effects of microgravity on multiple organs. To investigate the effects of microgravity on the central nervous system, we developed a unique organoid strategy for modeling specific regions of the brain that are affected by neurodegenerative diseases. We generated 3-dimensional human neural organoids from induced pluripotent stem cells (iPSCs) derived from individuals affected by primary progressive multiple sclerosis (PPMS) or Parkinson’s disease (PD) and non-symptomatic controls, by differentiating them toward cortical and dopaminergic fates, respectively, and combined them with isogenic microglia. The organoids were cultured for a month using a novel sealed cryovial culture method on the International Space Station (ISS) and a parallel set that remained on Earth. Live samples were returned to Earth for analysis by RNA expression and histology and were attached to culture dishes to enable neurite outgrowth. Our results show that both cortical and dopaminergic organoids cultured in LEO had lower levels of genes associated with cell proliferation and higher levels of maturation-associated genes, suggesting that the cells matured more quickly in LEO. This study is continuing with several more missions in order to understand the mechanisms underlying accelerated maturation and to investigate other neurological diseases. Our goal is to make use of the opportunity to study neural cells in LEO to better understand and treat neurodegenerative disease on Earth and to help ameliorate potentially adverse neurological effects of space travel.
Researchers at the Icahn School of Medicine at Mount Sinai have been awarded a $21 million grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH), to further advance understanding of an aging-related hormone known as follicle-stimulating hormone (FSH), including its potential role in obesity, osteoporosis, and Alzheimer’s disease. The work could lead to the development of new treatments for these and other conditions involving aging.
This is a collaborative effort with the NIA, led by Mone Zaidi, MD, PhD, Director of the Center for Translational Medicine and Pharmacology at Icahn Mount Sinai, and Clifford J. Rosen, MD, at the MaineHealth Institute for Research in Scarborough, Maine. Dr. Zaidi and Dr. Rosen are Program Directors, and principal investigators of individual projects are Anne Schafer, MD, at the University of California in San Francisco, as well as scientists at Icahn Mount Sinai, including Tony Yuen, PhD, Associate Professor and Research Director of the Center for Translational Medicine and Pharmacology, and Daria Lizneva, MD, PhD, Associate Professor of Pharmacological Sciences. Together, the investigators will work toward translating their findings into viable treatments for patients.
“We are delighted that the NIH has recognized the potential of our work by awarding this generous grant,” says Dr. Zaidi, the Mount Sinai Professor of Clinical Medicine at Icahn Mount Sinai. “Our focus for more than 25 years has been on identifying actionable targets for major public health diseases. This research offers the potential for a new drug for menopause and could also possibly help advance treatments for Alzheimer’s disease, obesity, and osteoporosis, affecting millions of people worldwide.”
Summary: A new study reveals that humans think at a rate of 10 bits per second, while sensory systems process a billion bits per second—100 million times faster. This highlights a paradox: why does the brain process thoughts so slowly when sensory input is so vast?
Researchers propose that the brain’s evolution prioritized focusing on single “paths” of thought, akin to navigating abstract concept spaces. These findings challenge notions of brain-computer interfaces enabling faster communication, as the brain’s inherent speed limit persists.
You can trigger a dizzy spell by standing up too fast, skipping lunch, spinning in a circle, or drinking too much alcohol. Dizziness can be linked to one’s ears, brain, heart, or metabolic system. The treatments, likewise, are heterogeneous. In benign paroxysmal positional vertigo, crystals in the inner ear canals become loose; physical repositioning, known as maneuvers, can usually treat it. For conditions of chronic dizziness called persistent postural perceptual dizziness (P.P.P.D.), vestibular rehabilitation and S.S.R.I.s, which normally treat depression and anxiety, seem to work better. Vestibular migraine is treated through the use of migraine-specific supplements or medications—which wouldn’t be advised for someone with the buildup of inner-ear fluid known as Ménière’s disease.
The sensation we call dizziness is a sort of general alarm system for the body—but just as a fire alarm can’t tell you where a fire is burning (or whether someone walked through the emergency exit by mistake), it doesn’t necessarily tell you what’s wrong. Dasgupta argued that diagnosing the causes of dizziness requires a lost clinical art known as anamnesis, or a holistic interview about the patient’s symptoms and their surrounding context. “This is like detective work,” he said. Diego Kaski, who treats vestibular patients as a consulting neurologist at the U.K.’s National Hospital for Neurology and Neurosurgery, tries to understand his patient’s symptoms by imagining that they are happening to him. He often relies on gestures: if people have vertigo, which includes the illusion of movement, “they might spin their finger or their hand around,” Kaski told me. Others will hold onto their heads or rock their upper bodies from side to side. Patient accounts tend to be psychological as well as physical. “You lose control of what your body is doing, and that can be quite a fearful experience,” Kaski said. Many dizzy people wonder whether they are dying.
While visiting doctor after doctor, I learned from a Google search about what sounded like a dizziness utopia: the German Center for Vertigo and Balance Disorders, or D.S.G.Z., in Munich. It was originally funded by the German federal government and, since 2019, has operated as an interdisciplinary center of the University Hospital of Munich.
Misfolded proteins may preserve postmortem brains well after other tissues have decayed.
By Kermit Pattison edited by Tanya Lewis
No part of our body is as perishable as the brain. Within minutes of losing its supply of blood and oxygen, our delicate neurological machinery begins to suffer irreversible damage. The brain is our most energy-greedy organ, and in the hours after death, its enzymes typically devour it from within. As cellular membranes rupture, the brain liquifies. Within days, microbes may consume the remnants in the stinky process of putrefaction. In a few years, the skull becomes just an empty cavity.
Tohoku University scientists created lab-grown neural networks using microfluidic devices, mimicking natural brain activity and enabling advanced studies of learning and memory.
The phrase “Neurons that fire together, wire together” encapsulates the principle of neural plasticity in the human brain. However, neurons grown in a laboratory dish do not typically adhere to these rules. Instead, cultured neurons often form random, unstructured networks where all cells fire simultaneously, failing to mimic the organized and meaningful connections seen in a real brain. As a result, these in-vitro models provide only limited insights into how learning occurs in living systems.
What if, however, we could create in-vitro neurons that more closely replicate natural brain behavior?
The glymphatic system becomes more active during sleep, especially during deep sleep, allowing for more effective waste clearance, said psychiatrist Dr. Jingduan Yang, founder of the Yang Institute of Integrative Medicine in Pennsylvania.
In a mouse study published in Science, researchers used tracers to monitor changes in cerebrospinal fluid flow. They found that during sleep, the interstitial, or intervening, space expanded by more than 60 percent, and the tracer influx increased. The brain’s clearance rate of beta-amyloid doubled during sleep (or under anesthesia) compared to the awake state.
